logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
FATE
Fate Therapeutics, Inc.
2.18
2 x 1.91
2 x 3.28
bid
ask
+
0.05
2.35%
2 @ 06:45 PM
2.17 -0.01 (0.46%)
Ytd122.45%
1y35.40%
2.10
day range
2.27
0.96
52 week range
3.11
Open2.13Prev Close2.13Low2.10High2.27Mkt Cap261.21M
Vol773.47KAvg Vol1.86MEPS-1.07P/EN/AForward P/E-0.99
Beta1.88Short Ratio3.10Inst. Own102.25%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-1250-d Avg2.47200-d Avg1.881yr Est6.31

FATE News

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
globenewswire.com
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag

CIRM backs Fate’s FT819 lupus trial
defenseworld.net
CIRM backs Fate’s FT819 lupus trial

What happened Fate Therapeutics, Inc. (NASDAQ: FATE) said the California Institute for Regenerative

benzinga.com
Fate Therapeutics Receives $15M CIRM Grant To Advance Phase 2 FT819 Trial In Lupus Nephritis

$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
globenewswire.com
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 G

$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial
benzinga.com
Fate Therapeutics Says Four Abstracts From Off-The-Shelf CAR T-Cell Programs Selected For Presentati

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
globenewswire.com
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfoli

SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-sta
benzinga.com
Fate Therapeutics To Present Clinical Data From Off-The-Shelf Anti-CD19 CAR T-Cell Product Candidate

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
globenewswire.com
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Prod

SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-sta

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
globenewswire.com
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Confer

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-sta

BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE
defenseworld.net
BlackRock Inc. Makes New Investment in Fate Therapeutics, Inc. $FATE

BlackRock Inc. acquired a new position in shares of Fate Therapeutics, Inc. (NASDAQ: FATE) in the un

Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead
seekingalpha.com
Fate Therapeutics: RECLAIM-LN Underway, Additional Clinical Updates Ahead

Fate Therapeutics has initiated the phase 2 RECLAIM-LN trial of FT819 in lupus nephritis, dosing the
benzinga.com
Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8

Piper Sandler analyst Edward Tenthoff reiterates Fate Therapeutics (NASDAQ:FATE) with a Overweigh
benzinga.com
Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5

Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and r
benzinga.com
Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and main
benzinga.com
Fate Therapeutics Highlights Initiation Of And Treatment Of First Patient In RECLAIM-LN, Phase 2 Pot

First patient dosed in an outpatient setting, discharged the same day; multiple patients in the proc

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
globenewswire.com
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Tr

First patient dosed in an outpatient setting, discharged the same day; multiple patients in the proc

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
zacks.com
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) came out with a quarterly loss of $0.25 per share versus the Zacks Consensu
benzinga.com
Fate Therapeutics Q2 EPS $(0.25) Beats $(0.27) Estimate, Sales $2.082M Beat $1.366M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.25) per share which beat the analys

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
globenewswire.com
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utiliz

FATE UNKNOWN: If CLARITY DIES Democrats KILLED IT, Lummis says
youtube.com
FATE UNKNOWN: If CLARITY DIES Democrats KILLED IT, Lummis says

Sen. Cynthia Lummis, R-Wyo., discusses the expected CLARITY Act vote, the budget agenda before reces

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag

Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
benzinga.com
Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Sess

US stock futures mostly higher, Nasdaq up by 100 points. Phoenix Education falls after cutting sales
benzinga.com
CORRECTION: Fate Therapeutics' Receives FDA Clearance For Its Investigational New Drug Application F

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
globenewswire.com
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product C

First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Mul
benzinga.com
Fate Therapeutics To Demonstrate Data On Its CAR T-cell Product Candidate FT819 At International Soc

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
globenewswire.com
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Can

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stag

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
globenewswire.com
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) --  Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-sta

Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive
seekingalpha.com
Fate Therapeutics: FT819 Progress Keeps My Bull Case Alive

Fate Therapeutics is a bet on their off-the-shelf cell therapies, which are now mostly centered on F

Fate Therapeutics Appoints Laura Hamill to Board of Directors
globenewswire.com
Fate Therapeutics Appoints Laura Hamill to Board of Directors

Accomplished global commercial operations leader brings deep experience launching and scaling biopha
benzinga.com
HC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Fate Therapeutics (NASDAQ:FATE) with a Bu
benzinga.com
Fate Therapeutics Showcases Data Featuring Its CAR T-Cell Programs At European Congress Of Rheumatol

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to brin
benzinga.com
Fate Therapeutics To Feature Data From Off-The-Shelf CAR T-Cell Programs At 2026 ASCO And EULAR Annu

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring
benzinga.com
Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.26) per share which beat the analys
benzinga.com
Fate Therapeutics To Present Data For Its Off-The-Shelf CAR T-Cell Programs At American Society Of G

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

10 Health Care Stocks Whale Activity In Today's Session
benzinga.com
10 Health Care Stocks Whale Activity In Today's Session
benzinga.com
Fate Therapeutics' FT819 Selected By FDA As Participant In Chemistry, Manufacturing And Controls Dev

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring
benzinga.com
Fate Therapeutics Announces That Data From Its Off-The-Shelf CAR T-Cell Programs FT819, FT839 And FT

Fate Therapeutics will present clinical and translational data from the systemic lupus erythematosus
benzinga.com
HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7

HC Wainwright & Co. analyst Robert Burns maintains Fate Therapeutics (NASDAQ:FATE) with a Buy
benzinga.com
Fate Therapeutics To Present Clinical Data From Its FT819 Candidate At Congress Of Clinical Rheumato

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to brin
benzinga.com
Fate Therapeutics Says Preclinical Data From Next-Gen, Off-The-Shelf CAR T-Cell Product Candidate, F

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring

Fate Therapeutics Q4 Earnings Summary & Key Takeaways
benzinga.com
Fate Therapeutics Q4 Earnings Summary & Key Takeaways

Earnings Summary: Fate Therapeutics Q4
benzinga.com
Earnings Summary: Fate Therapeutics Q4
benzinga.com
Fate Therapeutics Q4 EPS $(0.27) Misses $(0.26) Estimate, Sales $1.369M Beat $1.186M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.27) per share which missed the anal
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mi
benzinga.com
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Bi
benzinga.com
Earnings Scheduled For February 26, 2024

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly ear
benzinga.com
Earnings Scheduled For November 8, 2023

Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  On Thursday, 369 companies hit new 52-week lows.